Your browser doesn't support javascript.
loading
Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors.
Antunes, S V; Tangada, S; Stasyshyn, O; Mamonov, V; Phillips, J; Guzman-Becerra, N; Grigorian, A; Ewenstein, B; Wong, W-Y.
Afiliación
  • Antunes SV; UNIFESP, São Paulo, Brazil.
Haemophilia ; 20(1): 65-72, 2014 Jan.
Article en En | MEDLINE | ID: mdl-23910578
Factor replacement therapy for the treatment of moderate to severe haemophilia A and B can be complicated by the production of inhibitory alloantibodies to factor VIII (FVIII) or factor IX. Treatment with the nanofiltered anti-inhibitor coagulant complex, Factor Eight Inhibitor Bypassing Activity (FEIBA NF), is a key therapeutic option for controlling acute haemorrhages in patients with high-titre inhibitors or low-titre inhibitors refractory to replacement therapy. Given the high risk for morbidity and mortality in haemophilia patients with inhibitors to FVIII or FIX, we conducted this Phase 3 prospective study to evaluate whether prophylaxis with FEIBA NF is a safe and effective treatment option. Over a 1-year period, 17 subjects were treated prophylactically (85 ± 15 U kg(-1) every other day) while 19 subjects were treated on demand. The median (IQR) annualized bleeding rate (ABR) during prophylaxis was 7.9 (8.1), compared to 28.7 (32.3) during on-demand treatment, which amounts to a 72.5% reduction and a statistically significant difference in ABRs between arms (P = 0.0003). Three (17.6%) subjects (ITT) on prophylaxis experienced no bleeding episodes, whereas none treated on demand were bleeding episode-free. Total utilization of FEIBA NF for the treatment of bleeding episodes was significantly higher during on-demand therapy than prophylaxis (P = 0.0067). There were no differences in the rates of related adverse events between arms. This study demonstrates that FEIBA prophylaxis significantly reduces all types of bleeding compared with on-demand treatment, and the safety of prophylaxis is comparable to that of on-demand treatment.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Premedicación / Factores de Coagulación Sanguínea / Factor IX / Factor VIII / Hemofilia B / Hemofilia A Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Adolescent / Adult / Child / Humans / Male / Middle aged Idioma: En Revista: Haemophilia Asunto de la revista: HEMATOLOGIA Año: 2014 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Premedicación / Factores de Coagulación Sanguínea / Factor IX / Factor VIII / Hemofilia B / Hemofilia A Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Adolescent / Adult / Child / Humans / Male / Middle aged Idioma: En Revista: Haemophilia Asunto de la revista: HEMATOLOGIA Año: 2014 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Reino Unido